en · de · es · fr · pt
cjc-1295-notes.peptides7501.com › Topic › Handling Storage And Analytical Methods — Deep Dive

Handling Storage And Analytical Methods — Deep Dive

By Editorial Desk · published 2025-09-03 · last reviewed 2025-09-30 · Topic

This is a working overview of Reconstitution, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-09-30 and is reviewed periodically as new material appears.

Handling Storage And Analytical Methods

Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.

Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.

Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.

Mechanism and Pharmacokinetics

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Cjc-1295 at a glance

PropertyValueNotes
AppearanceWhite to off-white lyophilized powderVisual descriptor; not a measure of purity
Solubility classFreely soluble in waterAqueous dissolution may require gentle mixing
Typical storage (powder)−20 °C or below, desiccatedProtect from light and ambient moisture
Typical storage (solution)2–8 °C, short termFreeze aliquots where longer holding is needed
Purity assessmentReversed-phase HPLC, area percentValues depend on column, gradient, and detection wavelength

Compound Identity and Development History

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.

Related pages on this site

Background and Receptor Mechanism

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

Reference notes

== Electronic Associates, Inc. == In 1963, Finnigan and Uthe joined Electronic Associates, Inc. (EAI). The main research department of the company was based in Princeton, New Jersey, but Finnigan founded a new Scientific Instruments Division in Palo Alto, California. Finnigan's vision involved creation of a broad-based line of process-control instruments, beginning with the quadrupole mass spectrometer. Based on previous research at SRI, Finnigan was convinced that a market existed, but EAI and other companies such as IBM and Beckman Instruments were not interested in developing the quadrupole as a product at that time. Finnigan's group proposed to contract parts of the quadrupole production to SRI, but management at SRI were not interested in its commercial development either. Eventually Finnigan collaborated with staff from SRI, who supplied knowledge and expertise to help Finnigan's group bootstrap development of a prototype quadrupole analyzer at EAI. Because of the strong market demand the EAI division was able to sell more than 500 of these quadrupole residual gas analyzers between 1964 and 1966. Finnigan wanted to pursue development of computer-controlled instrumentation for a combined gas chromatograph (GC) and quadrupole mass spectrometer (MS). However, EAI's main focus was analog computers, and they were not interested in developing a computerized GC/MS. On December 31, 1966, after EAI unsuccessfully attempted to sell the division to Syntex Corporation, Finnigan submitted his resignation to EAI.

The work published by Banting, Best, Collip and Macleod represented the preparation of purified insulin extract suitable for use on human patients. Although Paulescu discovered the principles of the treatment, his saline extract could not be used on humans; he was not mentioned in the 1923 Nobel Prize. Ian Murray was particularly active in working to correct "the historical wrong" against Nicolae Paulescu. Murray was a professor of physiology at the Anderson College of Medicine in Glasgow, United Kingdom, the head of the department of Metabolic Diseases at a leading Glasgow hospital, vice-president of the British Association of Diabetes, and a founding member of the International Diabetes Federation. Murray wrote:

== Medicinal properties == Mashua has putative anaphrodisiac effects. It has been recorded by the Spanish chronicler Cobo that mashua was fed to their armies by the Inca Emperors, "that they should forget their wives". Studies of male rats fed on mashua tubers have shown a 45% drop in testosterone levels due to the presence of isothiocyanates. Mashua contains docosatetraenoylethanolamide, a cannabinoid structurally similar to anandamide that also acts on the cannabinoid (CB1) receptor among other structurally related compounds such as N–oleoyldopamine. Topical mashua in a 1% gel formulation has proven to increase the healing activities of open wounds in mice populations. Further studies are necessary to determine potential wound healing success for human application.

Sources: en.wikipedia.org

Notes from published material

A typical APCI source usually consists of three main parts: a sample inlet, a corona discharge needle, and an ion transfer region under intermediate pressure. In the case of the heated nebulizer inlet from an LC, as shown in the figure, the eluate flows at 0.2 to 2.0 mL/min into a pneumatic nebulizer which creates a mist of fine droplets. Droplets are vaporized by impact with the heated walls at 350–500 °C and carried by the nebulizer gas and an auxiliary gas into the ion molecule reaction region between the corona electrode and the exit counter-electrode. A constant current of 2–5 microamps is maintained from the corona needle. Sample ions are produced by ion-molecule reactions (as described below), and pass through a small orifice or tube into the ion transfer region leading to the mass spectrometer. Various geometries of ion source are possible, depending on application. When used with liquid chromatography, particularly at higher flow rates, the nebulizer is often positioned orthogonal to (or at a similarly steep angle to) the inlet of the mass spectrometer, so that solvent and neutral material does not contaminate the actual inlet of the mass spectrometer.

Caricain (EC 3.4.22.30, papaya peptidase A, papaya peptidase II, papaya proteinase, papaya proteinase III, papaya proteinase 3, proteinase omega, papaya proteinase A, chymopapain S, Pp) is an enzyme. This enzyme catalyses the following chemical reaction: Hydrolysis of proteins with broad specificity for peptide bonds, similar to those of papain and chymopapain This enzyme is isolated from the papaya plant, Carica papaya.

=== Analogues === Analogues of 6-HO-DET include diethyltryptamine (DET), 6-hydroxytryptamine (6-HT or 6-HO-T), 6-HO-DMT, 6-MeO-DMT, 6-methyl-DMT, 6-fluoro-DET, psilocin (4-HO-DMT), 4-HO-DET, bufotenin (5-HO-DMT), 7-HO-DMT, 5-HO-DET, 5-HO-DPT, and 5-HO-DiPT, among others.

=== Plant === Many plant expression vectors are based on the Ti plasmid of Agrobacterium tumefaciens. In these expression vectors, DNA to be inserted into plant is cloned into the T-DNA, a stretch of DNA flanked by a 25-bp direct repeat sequence at either end, and which can integrate into the plant genome. The T-DNA also contains the selectable marker. The Agrobacterium provides a mechanism for transformation, integration of into the plant genome, and the promoters for its vir genes may also be used for the cloned genes. Concerns over the transfer of bacterial or viral genetic material into the plant however have led to the development of vectors called intragenic vectors whereby functional equivalents of plant genome are used so that there is no transfer of genetic material from an alien species into the plant. Plant viruses may be used as vectors since the Agrobacterium method does not work for all plants. Examples of plant virus used are the tobacco mosaic virus (TMV), potato virus X, and cowpea mosaic virus. The protein may be expressed as a fusion to the coat protein of the virus and is displayed on the surface of assembled viral particles, or as an unfused protein that accumulates within the plant. Expression in plant using plant vectors is often constitutive, and a commonly used constitutive promoter in plant expression vectors is the cauliflower mosaic virus (CaMV) 35S promoter.

Sources: en.wikipedia.org

Frequently asked questions

How should the dry powder be stored?

Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.

Does a solution need to be used immediately?

There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.

Which analytical methods confirm identity?

Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.

How long does the albumin-binding form remain active?

Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.

Network